Vitiligo

Diagnosing Vitiligo and Improving Care Provider Awareness
November 30, 2021

Expert perspectives on the diagnosis of vitiligo and considerations for improving provider awareness in dermatologist and community settings.

Vitiligo: Clinical Presentations and Classifications
November 30, 2021

A comprehensive breakdown of the different classifications of vitiligo and how these may present clinically.

JAK Inhibitors: Drilling Down the Details
November 25, 2021

In this exclusive video interview, James Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the hype around the treatments.

Understanding the Psychosocial Impact of Vitiligo
November 23, 2021

Shared insight on the psychological and social impact of vitiligo, along with practical advice on how to communicate with and support patients.

An Overview of Vitiligo
November 23, 2021

Expert dermatologists Seemal Desai, MD, FAAD, and William Damsky, MD, PhD, provide an overview of vitiligo, as an autoimmune disorder, and its prevalence.

JAK Inhibitors Could Fill AD, Vitiligo, and AA Treatment Gaps
November 13, 2021

The potential of JAK inhibitors and other emerging medications could answer demand for more treatment options for these challenging skin conditions. Read down below.

Topical JAK Inhibitor May Treat Vitiligo
November 13, 2021

Ruxolitinib meets primary and secondary endpoints in phase 3 TRuE-V clinical trial program.

Differences in QoL Recorded for Vitiligo, Several Skin Diseases
November 11, 2021

Investigators reported that patients in the vitiligo group reported worse general health, and were willing to pay more than 40% of their income for a cure.

Scoring Vitiligo Using PROM Instrument CV-6
November 09, 2021

A recent study evaluated the efficacy of the patient reported outcome measure instrument Clinical Evolution-Vitiligo for scoring nonsegmental vitiligo.

Study: Maintaining Repigmentation in Vitiligo
November 09, 2021

A study in the Journal of the American Academy of Dermatology investigated the maintenance of results of ruxolitinib cream in patients with vitiligo.